Welcome to our dedicated page for Spectral AI news (Ticker: MDAIW), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.
Spectral AI, Inc. develops AI-driven medical diagnostics for wound care through its DeepView® System, a predictive diagnostic device and software platform for burn wound assessment. Company news centers on DeepView demonstrations at burn-care meetings, BARDA-supported development, FDA De Novo 510(k) submission activity, and preparation for U.S. commercialization.
Updates also cover quarterly and annual financial results, research and development revenue tied to government-supported work, cash resources, and executive or board leadership changes.
Spectral AI (NASDAQ: MDAI), developer of the AI-driven DeepView® System for burn healing prediction, has scheduled its fourth quarter and full year 2024 financial results announcement for March 27, 2025, after market close.
The company will host a conference call at 5:00 pm Eastern Time to discuss the results. Investors can participate by dialing 844-481-3008 (U.S.) or 412-317-1892 (International). A simultaneous webcast will be available through the Events & Presentations section of Spectral AI's Investor Relations website.
The DeepView® System, which received FDA Breakthrough Device Designation in 2018, utilizes multi-spectral imaging and AI algorithms to predict burn healing potential.
Spectral AI (NASDAQ: MDAI) has announced the completion of its debt obligations with Yorkville Advisors, strengthening its financial position. The company, which develops the AI-powered DeepView® System for burn healing prediction, maintains access to up to $17.5 million in additional financing through an existing standby equity purchase agreement.
The DeepView® System, which received FDA Breakthrough Device Designation in 2018, utilizes multi-spectral imaging and AI algorithms to predict burn healing potential. The company is progressing toward its FDA submission with the aim of implementing its technology in burn care institutions across the United States.
Spectral AI (NASDAQ: MDAI) has completed data analysis for its U.S. Burn Pivotal Study, one of the largest domestic burn studies ever conducted. The study validates the AI-driven algorithm used in the company's DeepView® System, which received FDA Breakthrough Device Designation in 2018.
The DeepView® System combines multispectral imaging with AI algorithms to predict burn wound healing potential, leveraging over 340 billion clinically-validated data points. The system provides immediate, binary predictions of wound healing on the day of injury, aiding clinical decision-making for treatment.
The company reports strong metrics when comparing the DeepView® System's performance to burn and emergency room physicians in determining wound healing potential. Spectral AI plans to submit a De Novo classification request to the FDA by June 2025 for the system's use in burn care.
Spectral AI (NASDAQ: MDAI) has completed pediatric enrollment at U.S. emergency departments for its U.S. Burn Pivotal Study, one of the largest domestic burn studies ever conducted. The study aims to validate the AI-driven algorithm used in the company's DeepView® System, which received FDA Breakthrough Device Designation in 2018.
The DeepView System combines multispectral imaging with an AI algorithm trained on over 340 billion clinically-validated data points to assess burn healing potential. The system provides immediate, binary predictions of wound healing to support clinical decision-making for treatment plans.
The company plans to submit a De Novo classification request to the FDA in the first half of 2025 based on the study's data.
Spectral AI (NASDAQ: MDAI), developer of the DeepView® System for burn healing prediction, has announced positive preliminary financial results for 2024. The company expects to report annual revenue surpassing its $28 million market guidance, marking the highest revenue in its history. The growth is attributed to increased focus on completing its BARDA contract, which has also led to improved gross profit margins. The company anticipates reporting over $5.0 million in cash. The DeepView® System, which received FDA Breakthrough Device Designation in 2018, utilizes multi-spectral imaging and algorithms to predict burn healing potential.
Spectral AI (NASDAQ: MDAI), developer of the AI-driven DeepView® System for burn healing prediction, has provided detailed instructions for retail investors on exercising publicly-traded warrants (NASDAQ: MDAIW). The process requires investors to: contact their broker's corporate actions department, ensure sufficient funds for the $2.75 per warrant exercise price plus fees, submit an exercise request with warrant details, and wait for MDAI common shares to be deposited into their account. If exercising fewer warrants than owned, investors will receive a new warrant for remaining shares. The company notes that individual brokers may have additional requirements.
Spectral AI (NASDAQ: MDAI), developer of the DeepView® System for burn healing prediction, announced receiving a 'moot' letter from Nasdaq on December 20, 2024, confirming its compliance with all applicable listing standards for continued listing on the Nasdaq Capital Market. The company's DeepView® System, which received FDA Breakthrough Device Designation in 2018, uses multi-spectral imaging and algorithms to predict burn healing potential. Dr. Michael DiMaio, Chairman of the Board, expressed satisfaction with maintaining compliance and highlighted ongoing progress towards FDA submission.
Spectral AI (NASDAQ: MDAI) announced it believes it has regained compliance with Nasdaq Listing Rule 5550(b)(2) by maintaining a market value of listed securities above $35 million for 10 consecutive business days. The company, which develops the DeepView® System (an AI-driven technology with FDA Breakthrough Device Designation for burn healing prediction), has notified Nasdaq and awaits official confirmation of compliance.
Spectral AI (NASDAQ: MDAI) announced significant progress in the development of its DeepView® System, an AI-driven wound diagnostics platform. National burn care leaders have contributed over 511 in-person physician days for training and validation studies, plus 250 additional days in proof-of-concept studies. The collaboration includes three former/current presidents and ten board members of the American Burn Association, along with two editors-in-chief of leading burn journals.
The DeepView® System, which received FDA Breakthrough Device Designation in 2018 and UKCA mark for burn indications, combines advanced algorithms with medical imaging to predict wound healing potential. This unprecedented level of expert participation enhances the dataset's credibility and reliability, positioning DeepView® as a potential future standard in burn care diagnostics.
Spectral AI (NASDAQ: MDAI) has completed software enhancements for its DeepView SnapShot® M and DeepView AI-Burn® system in the UK. The updates, based on real-world clinician feedback, aim to improve diagnostic accuracy, workflow integration, and patient care.
The regulatory milestone allows implementation of updated software on currently deployed systems in the UK, where the devices are authorized as separate products. The enhancement also benefits Australian burn centers operating under the Approved Prescriber Program, ensuring access to Spectral AI's advanced diagnostic technology.
According to Board Chairman Dr. J. Michael DiMaio, UK authorization and technical documentation support device usage in both UK hospitals and Australian TGA approval processes. The company reports encouraging feedback from UK implementations.